FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2751837560> ?p ?o ?g. }

• W2751837560 abstract "Abstract INTRODUCTION. In classical Hodgkin lymphoma (cHL), the low representation (~5%) of Hodgkin-Reed-Sternberg cells (HRS) challenged tumor genotyping on the tissue biopsy. Cell free DNA (cfDNA) is shed into the blood by tumor cells and can be used as source of tumor DNA for the identification of somatic mutations, track clonal evolution of tumors and detect minimal residual disease during therapy. AIMS. The study aimed at: i) showing that cfDNA mirrors the genetics of HRS cells in cHL patients; ii) characterizing the mutational profile of a large cohort of newly diagnosed and chemorefractory cHL; iii) identifying molecular prognostic subtypes; iv) early detecting residual disease during therapy; and v) longitudinally tracking tumor clonal evolution under different treatment modalities. METHODS. The study included 80 newly diagnosed cHL and 32 chemorefractory cHL. The following biological material was analyzed: i) cfDNA from plasma collected at diagnosis, during ABVD courses, at refractory progression, before and during therapy with brentuximab or nivolumab; and ii) normal germline genomic DNA (gDNA) from granulocytes. For comparative purposes, paired tumor gDNA from microdissected HRS cells of 13 cases was also analyzed. A targeted resequencing panel optimized to include the coding exons and splice sites of 77 genes recurrently mutated in B-cell lymphomas was used for genotyping. Ultra-deep next-generation sequencing (NGS) of the gene panel was performed on NexSeq 500 (Illumina) using the CAPP-seq library preparation strategy (NimbleGen). RESULTS. In cHL patients, cfDNA surrogated gDNA from HRS cells, since it harbored 87.5% of the tumor confirmed mutations. Genes recurrently affected by non-synonymous somatic mutations in >20% of cHL included STAT6 (37.5%), TNFAIP3 (35%), and ITPKB (27.5%) (Fig. 1A). Mutations clustered in major pathways, including NF-κB, PI3K-AKT, cytokine and NOTCH signaling, and immune evasion. ITPKB mutations: i) were quite specific for cHL, being rare or absent in other lymphomas; ii) caused the subcellular delocalization of the protein in primary HRS cells of mutated patients; iii) correlated with clues of PI3K-AKT signaling activation both at gene expression and protein levels; and iv) consistent with the positioning of ITPKB downstream PI3K in the pathway, associate with resistance to PI3K inhibitors. Mutations of CD58, encoding a co-stimulatory molecule for T-cells, associated with short PFS independent of interim PET/CT results, pointing to immune escape genetic lesions as biomarkers of aggressive disease (Fig. 1B). Newly diagnosed and chemorefractory cHL shared a largely overlapping mutational landscape. TP53 mutations were not enriched in refractory cHL as instead commonly found in other types of refractory B-cell tumors. Conversely, more TET2 mutations were documented in refractory cHL, including newly acquired mutation, thus signaling towards aberrant DNA methylation programming as a mechanism of resistance in cHL with potential therapeutic implications. By longitudinal analysis, in patients relapsing under/after chemotherapy or brentuximab vedotin, pre-treatment/relapse tumor pairs branched through the acquisition of phase specific mutations from an ancestral clone, that always persisted (Fig. 1C). Conversely, in patients maintained under nivolumab, clones were cyclically suppressed and replaced by completely novel clones. We utilized the change in circulating tumor cfDNA load from baseline to interim timepoint to predict the best response to ABVD and to complement interim PET/CT in anticipating cure. A drop of 100-fold or 2-log drop in tumor cfDNA after 2 ABVD courses associated with an eventual complete response and cure. All cured patients that were inconsistently judged as interim PET/CT positive turned out to have a >2 log drop in tumor cfDNA. A drop of less than 2-log in tumor cfDNA after 2 ABVD courses associated with an eventual progression. All relapsed patients that were inconsistently judged as interim PET/CT negative turned out to have a Download : Download high-res image (196KB) Download : Download full-size image Figure 1 . Disclosures Stathis: Celgene: Research Funding; Pfizer: Research Funding; Merck: Research Funding; Roche: Consultancy, Other: Advisory board; Amgen: Honoraria. Bertoni: Acerta Pharma: Research Funding; Bayer: Research Funding; Cellestia: Research Funding; Menarini: Research Funding; Piqur: Research Funding; Immunogen: Research Funding. Santoro: Merck: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees. Zucca: Bayer: Consultancy, Other: Advisory Role; Jannsen: Consultancy, Honoraria, Other: Advisory role; Takeda: Consultancy, Other: Advisory role; Celltrion Healthcare: Consultancy, Other: Advisory Role; Celltrion Healthcare: Consultancy, Other: Advisory Role; Celgene: Honoraria, Research Funding; Sandoz: Consultancy, Other: Advisory role; Bayer: Consultancy, Other: Advisory Role; Gilead Science: Consultancy, Other: Advisory role; Roche: Honoraria, Research Funding; Jannsen: Consultancy, Honoraria, Other: Advisory role; Roche: Advisory role, Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Mundipharma: Research Funding; Mundipharma: Research Funding; Gilead Science: Consultancy, Other: Advisory role; Takeda: Consultancy, Other: Advisory role; Sandoz: Consultancy, Other: Advisory role. Gaidano: Roche: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Amgen: Consultancy, Honoraria. Carlo-Stella: ADC Therapeutics: Research Funding." @default.
• W2751837560 created "2017-09-15" @default.
• W2751837560 creator A5000611970 @default.
• W2751837560 creator A5002654651 @default.
• W2751837560 creator A5002703557 @default.
• W2751837560 creator A5005592897 @default.
• W2751837560 creator A5007167867 @default.
• W2751837560 creator A5009234092 @default.
• W2751837560 creator A5013201388 @default.
• W2751837560 creator A5015128036 @default.
• W2751837560 creator A5015790909 @default.
• W2751837560 creator A5017631081 @default.
• W2751837560 creator A5018323809 @default.
• W2751837560 creator A5021191432 @default.
• W2751837560 creator A5023810403 @default.
• W2751837560 creator A5027184783 @default.
• W2751837560 creator A5033613491 @default.
• W2751837560 creator A5039187831 @default.
• W2751837560 creator A5039752042 @default.
• W2751837560 creator A5041745367 @default.
• W2751837560 creator A5042459008 @default.
• W2751837560 creator A5042629318 @default.
• W2751837560 creator A5043302833 @default.
• W2751837560 creator A5045311601 @default.
• W2751837560 creator A5048622832 @default.
• W2751837560 creator A5049503939 @default.
• W2751837560 creator A5053689328 @default.
• W2751837560 creator A5066518317 @default.
• W2751837560 creator A5071347282 @default.
• W2751837560 creator A5075117420 @default.
• W2751837560 creator A5080909838 @default.
• W2751837560 creator A5082045927 @default.
• W2751837560 creator A5088953061 @default.
• W2751837560 date "2017-09-01" @default.
• W2751837560 modified "2023-10-01" @default.
• W2751837560 title "Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy" @default.
• W2751837560 doi "https://doi.org/10.1016/j.clml.2017.07.130" @default.
• W2751837560 hasPublicationYear "2017" @default.
• W2751837560 type Work @default.
• W2751837560 sameAs 2751837560 @default.
• W2751837560 citedByCount "0" @default.
• W2751837560 crossrefType "journal-article" @default.
• W2751837560 hasAuthorship W2751837560A5000611970 @default.
• W2751837560 hasAuthorship W2751837560A5002654651 @default.
• W2751837560 hasAuthorship W2751837560A5002703557 @default.
• W2751837560 hasAuthorship W2751837560A5005592897 @default.
• W2751837560 hasAuthorship W2751837560A5007167867 @default.
• W2751837560 hasAuthorship W2751837560A5009234092 @default.
• W2751837560 hasAuthorship W2751837560A5013201388 @default.
• W2751837560 hasAuthorship W2751837560A5015128036 @default.
• W2751837560 hasAuthorship W2751837560A5015790909 @default.
• W2751837560 hasAuthorship W2751837560A5017631081 @default.
• W2751837560 hasAuthorship W2751837560A5018323809 @default.
• W2751837560 hasAuthorship W2751837560A5021191432 @default.
• W2751837560 hasAuthorship W2751837560A5023810403 @default.
• W2751837560 hasAuthorship W2751837560A5027184783 @default.
• W2751837560 hasAuthorship W2751837560A5033613491 @default.
• W2751837560 hasAuthorship W2751837560A5039187831 @default.
• W2751837560 hasAuthorship W2751837560A5039752042 @default.
• W2751837560 hasAuthorship W2751837560A5041745367 @default.
• W2751837560 hasAuthorship W2751837560A5042459008 @default.
• W2751837560 hasAuthorship W2751837560A5042629318 @default.
• W2751837560 hasAuthorship W2751837560A5043302833 @default.
• W2751837560 hasAuthorship W2751837560A5045311601 @default.
• W2751837560 hasAuthorship W2751837560A5048622832 @default.
• W2751837560 hasAuthorship W2751837560A5049503939 @default.
• W2751837560 hasAuthorship W2751837560A5053689328 @default.
• W2751837560 hasAuthorship W2751837560A5066518317 @default.
• W2751837560 hasAuthorship W2751837560A5071347282 @default.
• W2751837560 hasAuthorship W2751837560A5075117420 @default.
• W2751837560 hasAuthorship W2751837560A5080909838 @default.
• W2751837560 hasAuthorship W2751837560A5082045927 @default.
• W2751837560 hasAuthorship W2751837560A5088953061 @default.
• W2751837560 hasConcept C104317684 @default.
• W2751837560 hasConcept C113968399 @default.
• W2751837560 hasConcept C121608353 @default.
• W2751837560 hasConcept C135763542 @default.
• W2751837560 hasConcept C143998085 @default.
• W2751837560 hasConcept C2778461978 @default.
• W2751837560 hasConcept C2779529041 @default.
• W2751837560 hasConcept C2779823535 @default.
• W2751837560 hasConcept C31467283 @default.
• W2751837560 hasConcept C502942594 @default.
• W2751837560 hasConcept C54355233 @default.
• W2751837560 hasConcept C71924100 @default.
• W2751837560 hasConcept C86803240 @default.
• W2751837560 hasConceptScore W2751837560C104317684 @default.
• W2751837560 hasConceptScore W2751837560C113968399 @default.
• W2751837560 hasConceptScore W2751837560C121608353 @default.
• W2751837560 hasConceptScore W2751837560C135763542 @default.
• W2751837560 hasConceptScore W2751837560C143998085 @default.
• W2751837560 hasConceptScore W2751837560C2778461978 @default.
• W2751837560 hasConceptScore W2751837560C2779529041 @default.
• W2751837560 hasConceptScore W2751837560C2779823535 @default.
• W2751837560 hasConceptScore W2751837560C31467283 @default.
• W2751837560 hasConceptScore W2751837560C502942594 @default.
• W2751837560 hasConceptScore W2751837560C54355233 @default.
• W2751837560 hasConceptScore W2751837560C71924100 @default.
• W2751837560 hasConceptScore W2751837560C86803240 @default.
• W2751837560 hasLocation W27518375601 @default.

• next